Abstract： Objective To evaluate the clinical efficacy and adverse events of recombinant human interleukin-11(rhIL-11) in the prevention of thrombocytopenia induced by craniospinal irradiation. Methods In this randomized control study, 100 patients were randomly divided into A (rhIL-11 group, n=50) and B groups (control group, n=50). In the A group, subcutaneous injection of rhIL-11 was delivered at a dose of 50 μg/kg/d, once daily when the platelet count was< 100×109/L during radiotherapy or decreased by> 50% compared with the baseline level. The administration of rhIL-11 was terminated when the platelet count was ≥ 200×109/L. In the B group, the same protocol was conducted when the platelet count was< 50×109/L and terminated until the platelet count was ≥ 100×109/L. The clinical efficacy was assessed in 92 patients. Subcutaneous injection of rhIL-11 could significantly elevate the minimal platelet count during craniospinal irradiation (P<0.01), considerably shorten the duration of thrombocytopenia (P<0.01) and effectively shorten the duration of radiotherapy (P<0.01). Main adverse events included mild pain at the injection site, sclerosis, redness and fatigue, etc. Conclusions Injection of rhIL-11 can significantly enhance the platelet count, effectively reduce the incidence of thrombocytopenia throughout craniospinal irradiation, guarantee the success of radiotherapy and yield mild adverse events.
Fang Henghu,Han Qing,Zhao Xiangfei et al. Clinical research of thrombocytopenia induced by craniospinal irradiation[J]. Chinese Journal of Radiation Oncology, 2018, 27(8): 727-728.
[1] Johnson DR,Guerin JB,Giannini C,et al.2016 Updates to the WHO brain tumor classification system:what the radiologist needs to know[J].Radiographics,2017,37(7):2164-2180. [2] 储大同,徐兵河,宋三泰,等.重组人白细胞介素-11预防化疗所致血小板减少的临床研究[J].中华肿瘤杂志,2003,25(3):272-274. Chu DT,Xu BH,Song ST,et al. Clinical study of recombinant human interleukin-11 in prevention of thrombocytopenia induced by chemotherapy[J].Chin J Oncol,2003,25(3):272-274.
2018, Vol. 27 
